The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
Active, not recruiting · Not applicable · NCT05409976
Conditions: Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
At a glance
- Research payments reported, 2025
- $25,941
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 136
About the trial
- Sponsor
- W.L.Gore & Associates
- Tested
- GORE® VIAFORT Vascular Stent (device)
- Dates
- Started 2022-10-25; completion 2030-05-09
- Results posted
- Yes
This study is a prospective, multicenter, non-randomized, single-arm study to evaluate the performance, safety, and efficacy of the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) for treatment of symptomatic inferior vena cava obstruction with or without combined iliofemoral obstruction in adult patients.
From ClinicalTrials.gov, last updated 2026-08-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
W. L. Gore & Associates, Inc. reported $25,941 in research payments for this study in 2025 (2 payments).
Products named: Product in Development
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Steven D. Abramowitz, M.D. Vascular Surgery · Washington, DC
- Natalie Sridharan Vascular Surgery · Pittsburgh, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Medstar Health Research Institute $24,037
- University of Pittsburgh Physicians $1,904
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.